Adipose Tissue Dysregulation and Reduced Insulin Sensitivity in Non-Obese Individuals with Enlarged Abdominal Adipose Cells by Hammarstedt, Ann et al.
 
Adipose Tissue Dysregulation and Reduced Insulin Sensitivity in
Non-Obese Individuals with Enlarged Abdominal Adipose Cells
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Hammarstedt, Ann, Timothy E. Graham, and Barbara Kahn.
2012. Adipose tissue dysregulation and reduced insulin
sensitivity in non-obese individuals with enlarged abdominal
adipose cells. Diabetology & Metabolic Syndrome 4:42.
Published Version doi:10.1186/1758-5996-4-42
Accessed February 19, 2015 11:54:56 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10579260
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAARESEARCH Open Access
Adipose tissue dysregulation and reduced insulin
sensitivity in non-obese individuals with enlarged
abdominal adipose cells
Ann Hammarstedt
1*, Timothy E Graham
2 and Barbara B Kahn
2
Abstract
Background: Obesity contributes to Type 2 diabetes by promoting systemic insulin resistance. Obesity causes
features of metabolic dysfunction in the adipose tissue that may contribute to later impairments of insulin action in
skeletal muscle and liver; these include reduced insulin-stimulated glucose transport, reduced expression of GLUT4,
altered expression of adipokines, and adipocyte hypertrophy. Animal studies have shown that expansion of adipose
tissue alone is not sufficient to cause systemic insulin resistance in the absence of adipose tissue metabolic
dysfunction. To determine if this holds true for humans, we studied the relationship between insulin resistance and
markers of adipose tissue dysfunction in non-obese individuals.
Method: 32 non-obese first-degree relatives of Type 2 diabetic patients were recruited. Glucose tolerance was
determined by an oral glucose tolerance test and insulin sensitivity was measured with the hyperinsulinaemic-
euglycaemic clamp. Blood samples were collected and subcutaneous abdominal adipose tissue biopsies obtained
for gene/protein expression and adipocyte cell size measurements.
Results: Our findings show that also in non-obese individuals low insulin sensitivity is associated with signs of
adipose tissue metabolic dysfunction characterized by low expression of GLUT4, altered adipokine profile and
enlarged adipocyte cell size. In this group, insulin sensitivity is positively correlated to GLUT4 mRNA (R=0.49,
p=0.011) and protein (R=0.51, p=0.004) expression, as well as with circulating adiponectin levels (R=0.46,
0=0.009). In addition, insulin sensitivity is inversely correlated to circulating RBP4 (R=−0.61, 0=0.003) and
adipocyte cell size (R=−0.40, p=0.022). Furthermore, these features are inter-correlated and also associated with
other clinical features of the metabolic syndrome in the absence of obesity. No association could be found
between the hypertrophy-associated adipocyte dysregulation and HIF-1alpha in this group of non-obese
individuals.
Conclusions: In conclusion, these findings support the concept that it is not obesity per se, but rather metabolic
dysfunction of adipose tissue that is associated with systemic insulin resistance and the metabolic syndrome.
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There is currently a global epidemic of Type 2 diabetes
due to recent changes in lifestyle. Obesity is the major
factor promoting the diabetes epidemic and this suggests
that the expanded adipose tissue is a major driver
through induction of obesity-associated insulin resist-
ance [1]. In agreement with this concept, insulin resist-
ance is observed locally in the adipose tissue long before
glucose intolerance develops [2]. Early cellular markers
of insulin resistance in adipose tissue are reduced adi-
pose cell GLUT 4 and IRS 1 protein expression [3-6].
Interestingly, this is seen around four times more fre-
quently in individuals with a genetic predisposition for
type 2 diabetes than in subjects lacking a genetic predis-
position [5]. The reason for this is currently unclear but
the phenomenon suggests an association between gen-
etic predisposition for type 2 diabetes and a dysregulated
adipose tissue.
We have recently shown that the ability to differentiate
preadipocytes into adipocytes is reduced in cells from
adipose tissue characterized by enlarged fat cells [7].
This seems to predominantly be due to impaired preadi-
pocyte differentiation rather than a lack of early precur-
sor cells including mesenchymal stem cells [7]. These
results clearly indicate that adipose tissue dysfunction is
related to adipose cell enlargement. Experiments in ani-
mal models also support this concept since, for instance,
overexpressing adiponectin in adipose tissue leads to a
marked hypercellular obesity without adipose cell en-
largement and the animals are at least as insulin sensi-
tive as the lean wildtype mice [8]. In addition, over
expression of GLUT4 in adipocytes leads to hyperplastic
obesity and enhanced glucose tolerance [9]. The
increased GLUT4 in fat even overcomes insulin resist-
ance in muscle resulting from genetic deletion of
GLUT4 in muscle [10]. Clearly, adipose tissue function
is important for whole body glucose homeostasis.
In this study we examined if adipose tissue dysfunction
is more closely related to adipocyte hypertrophy rather
than to BMI in man. We investigated GLUT4 expression
in adipose cells as a marker of adipose tissue dysregula-
tion in relation to whole-body insulin sensitivity, serum
levels of adiponectin and RBP4, as well as the relation-
ship to adipose cell size in a population of non-obese
subjects.
Material and methods
Subjects
All subjects included in the study were healthy non-
diabetic offspring of parents with type 2 diabetes. Clinical
and biochemical characteristics of the study population
are shown in Table 1. The study was approved by the
ethical committee of the University of Gothenburg and
performed in accordance with the Declaration of
Helsinki. Written consent was obtained from each subject.
Biochemical and anthropometric measures
Height and weight were measured to the nearest cm and
0.1 kg and BMI calculated as kg body weight divided by
height (m) squared. Fasting blood samples were drawn
after an over night fast followed by an OGTT (75 g glu-
cose) to evaluate glucose tolerance (blood samples were
taken at 0, 30, 90 and 120 min). Circulating plasma glu-
cose was determined using a photometric method by the
accredited central hospital laboratory and insulin con-
centrations by a micro-particle enzyme immunoassay
(Abbott Laboratories, Tokyo, Japan). At 60 min after a
glucose bolus a hyperinsulinaemic-euglycaemic clamp
was initiated and carried out for the next 120 min (insu-
lin infusion 40 mU, m
-2, min
-2) to evaluate insulin sensi-
tivity. Blood glucose was clamped at 5 mmol/l by
infusion of 20% glucose at various rates according to the
blood glucose measurements performed at 5 min inter-
vals. The mean amount of glucose infused during the
last hour was used to calculate the rate of whole-body
glucose uptake. Non-esterified fatty acids in serum were
measured by an enzymatic colorimetric method (Wako
Table 1 Clinical characteristics of the studied individuals
Variable Mean ± SD
Sex (male/female) 10/22
Age (years) 42±6
Height (m) 1.73±0.08
Weight (kg) 75.7±10.3
BMI (kg/m2) 25.2±2.4
Waist (cm) 87±8
Hip (cm) 104±5
WHR 0.83±0.08
Glucose (mmol) 4.9±0.5
Insulin (mU/L) 7.1±3.1
GIR (mg/min/kgLBM) 12.6±3.9
OGTT 2 h glucose (mmol/l) 6.5±1.7
HOMA-index 1.68±0.84
HbA1c (%) 4.14±0.26
s-triglycerides (mmol/l) 1.08±0.65
s-HDL cholesterol (mmol/l) 1.51±0.46
s-LDL cholesterol (mmol/l) 2.86±0.89
Blood pressure syst (mmHg) 116±9
Blood pressure diast (mmHg) 73±7
s-Adiponectin (ug/ml) 10.8±4.3
s-RBP4 (RQ) 1.40±0.38
Adipocyte cell size (ug) 0.47±0.17
GIR Glucose infusion rate during the euglycemic clamp.
OGTT oral glucose tolerance test.
WHR waist/hip ratio.
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concentrations were determined with an automated
Cobra Mira analyser (Hoffman-LaRoche, Basel,
Switzerland). Circulating adiponectin levels were measured
in serum by a human adiponectin ELISA-kit (B-Bridge
International, Sunnyvale, CA, USA) according to the manu-
f a c t u r e r si n s t r u c t i o n sa n ds e r u mR B P 4b yq u a n t i t a t i v e
Western Blot [11]. Information of physical activity was col-
lected by a questioner and expressed as number of times
per week of exercise at least 20 min.
Adipocyte isolation
Human abdominal subcutaneous adipose tissue was
obtained in the fasting state by needle biopsy. Isolation
of adipocytes was performed essentially as previously
described [7]. Briefly, biopsies were washed to remove
traces of blood and treated with collagenase (1 mg/ml)
(Sigma, St Louise, MO, USA) for ~60 min at 37°C in a
shaking waterbath. Isolated adipocytes were filtered
through a 250 μm nylon mesh, washed with fresh
medium. Adipocyte cells were placed on a siliconized
glass slide and 100 consecutive cell diameters were mea-
sured with a calibrated ocular.
Cell lysate and Western blot
Isolated human adipocytes were separated from medium
by centrifugation through dinonyl phthalate. Lysis buffer
was added, samples briefly vortexed and rocked for 2 h
at 4°C. Insoluble material was sedimented by centrifuga-
tion and supernatant collected and stored at −80°C prior
to use [12]. Protein concentration was measured using
the bicinchonic acid method (Pierce, Rockford, IL,
USA). Protein were separated on SDS-PAGE as
described [4] and immunoblotted with an anti-GLUT4
antibody (Chemicon, Temecula, CA, USA).
RNA extraction and quantification
Total cellular RNA was extracted from abdominal sub-
cutaneous adipose tissue biopsies with the guanidinium
thiocyanate method as described [13]. Gene expression
was analyzed with the ABI PRISM 7900HT sequence de-
tection system (TaqMan, Applied biosystems, Foster
City, CA, USA). Gene-specific primers and probes were
designed using the Primer Express software (Applied
biosystems, Foster City, CA, USA) GLUT4: Fp TCTG
GCATCAATGCTGTTTTCTAT, Rp ACCAACAACAC
CGAGACCAAG, probe TGACCACACCAGCTCCTAT
GGTGGC; C/EBPalpha: Fp CCAAGAAGTCGGTGGA
CAAGA, Rp GCGCACCGCGATGTTGTT, probe CGC
CGCACCCGGTACTCGTT; HIF-1alpha: Fp AAATACA
TGGGATTAACTCAGTTTGAA, Rp GGCCATTTCTG
TGTGTAAGCAT, probe CATCCATGTGACCATGAG
GAAATGAGAGA; VEGF: Hs00173626_m1 (Applied
Biosystems, Foster City, CA, USA). Each sample was run
in duplicate and the quantity of a particular gene in each
sample was normalized to ribosomal 18 s RNA.
Statistical analysis
All data are presented as mean ± SD. Data was tested
for normality and, if appropriate, Log transformed. Lin-
ear correlations and adjustment for gender and exer-
cise were performed using PASWstatistics (SPSS
Inc). P-value <0.05 was considered to be significant.
P-values were adjusted for multiple testing using the
Bonferroni-Holm correction algorithm (SAS).
Results
We characterized adipose tissue GLUT 4 protein and
gene expression in 32 individuals with BMI range 20.8-
29.7 and a genetic predisposition for type 2 diabetes
(first degree relatives; FDR). These individuals were part
of a large inter-European study, EUGENE2, relating
phenotype to genotype. The inclusion criteria and phe-
notyping procedures have been reported previously [14].
The clinical characteristics of the cohort studied here
are shown in Table 1.
Body composition in relation to insulin sensitivity
Insulin sensitivity measured with the euglycemic clamp
technique was significantly negatively correlated with
adipose cell size, as expected [15] as well as with waist/
hip ratio while the correlation to BMI was not significant
in these non-obese individuals (Table 2). Furthermore,
insulin sensitivity correlated with, s-HDL-cholesterol,
total s-adiponectin levels, and adipose tissue GLUT 4
protein expression and mRNA levels, and inversely with
s-triglycerides and s-RBP4 (Table 2). Adjusting for
gender did not significantly alter the results except for
s–triglycerides that were no longer significant after ad-
justment (p=0.056), also after adjustment for gender
and exercise s-HDL was no longer significantly corre-
lated with insulin sensitivity (p=0.059). Adjusting for
exercise alone did not affect the results. These results
support the concept that insulin sensitivity is more
closely related to adipose cell size and adipose tissue dis-
tribution than to BMI.
Abdominal adipose cell size and markers of insulin
sensitivity
Adipose cell size also correlated with other known meta-
bolic consequences of insulin resistance including circu-
lating insulin levels and total triglyceride levels (Table 2
and Figure 1a).
More importantly, adipose cell size, like waist/hip ratio,
correlated negatively with circulating adiponectin levels.
BMI also tended to correlate with circulating adiponectin
levels. The correlation was, however, not as strong as
with adipocyte cell size (Figure 1b). Furthermore, adipose
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GLUT4 gene expression and a trend for this was also
found at protein level (Figure 1c). In addition, a border-
line significant negative correlation was found with circu-
lating RBP4 levels (Table 2) while no association could be
found between circulating RBP4 and BMI.
Adjusting for gender resulted in a statistical significant
correlations between cell size and GLUT4 protein
(p=0.033) and also negatively with RBP4 (p=0.046) and
did not significantly affect other associations. Adjusting
for exercise did not change the results.
Adipose tissue GLUT 4 and circulating levels of insulin
sensitivity or resistance markers
We then examined GLUT4 expression in the adipose
tissue in relation to insulin sensitivity and circulating
adiponectin and RBP4 levels. Circulating adiponectin
levels tended to correlate positively with GLUT4 gene
and protein expression. Adjusting for exercise did, how-
ever, result in a significant correlation between adipo-
nectin and GLUT4 mRNA (p=0.041) whereas adjusting
for gender made the associations non-significant. Adipo-
nectin correlated negatively with serum RBP4 levels
(Figure 2), which was not affected by exercise. We also
examined the expression of C/EBPalpha, an important
transcription factor for adipocyte insulin sensitivity [16],
and found, as expected, a significant and positive correl-
ation with both GLUT4 protein and gene expression
(data not shown). Adiponectin levels also correlated
positively with degree of insulin sensitivity (Table 2),
HDL-cholesterol and negatively with fasting insulin and
HbA1c levels (Table 3). Thus, both markers of insulin
sensitivity; i.e.; GLUT4 expression in the adipose tissue
and serum adiponectin, which is only expressed in and
secreted by the adipose cells, are closely correlated to
each other and show a similar profile.
Adipose tissue dysregulation, inflammation and hypoxia
Adipose tissue inflammation is increased in hypertrophic
obesity and promotes dysregulated adipose tissue biology
[17]. In line with these findings, we have previously
shown that the inflammatory cytokine IL-6 is elevated in
hypertropic obesity and that the interstitial concentra-
tion correlates with cell size [18]. Another possible can-
didate for adipose tissue dysregulation associated with
hypertrophic obesity is HIF-1alpha since cellular hypoxia
has been demonstrated to occur when the adipose cells
expands [19]. However, we found no correlation between
either adipose cell size, insulin sensitivity or any of the
markers of insulin resistance with HIF-1alpha mRNA
levels or the HIF-1alpha-induced gene VEGF in these
non obese subjects (Table 4). Adjusting for gender and/
or exercise did not affect the results. The results from
these analyses may have been affected by the reduced
number of subjects included due to limited mRNA or
tissue availability.
Table 2 Correlation between insulin sensitivity and adipose cell size with phenotype
Insulin sensitivity Adipocyte cell size
All Men Women All Men Women
R-
value
P-value
(Pcorr)
R-
value
P-value
(Pcorr)
R-
value
P-value
(Pcorr)
R-
value
P-value
(Pcorr)
R-
value
P-value
(Pcorr)
R-
value
P-value
(Pcorr)
BMI −0.05 0.79 (0.98) −0.06 0.88 (1) 0.07 0.77 (1) 0.53 0.002 (0.022) 0.70 0.025 (0.25) 0.43 0.046 (0.30)
WHR −0.49 0.004 (0.044) −0.36 0.31 (1) −0.49 0.02 (0.22) 0.36 0.041 (0.25) 0.54 0.11 (0.77) 0.47 0.026 (0.26)
Glucose −0.13 0.49 (0.98) −0.55 0.10 (1) 0.16 0.47 (1) 0.30 0.092 (0.28) 0.48 0.16 (0.84) 0.21 0.36 (0.72)
Insulin −0.34 0.055 (0.22) −0.66 0.037 (0.44) −0.21 0.36 (1) 0.52 0.002 (0.022) 0.64 0.045 (0.41) 0.49 0.028 (0.26)
HbA1c −0.24 0.18 (0.18) −0.44 0.21 (1) −0.11 0.63 (1) 0.28 0.13 (0.28) 0.43 0.21 (0.84) 0.21 0.34 (0.72)
GIR ––––-- −0.40 0.022 (0.18) −0.40 0.26 (0.84) −0.44 0.043 (0.30)
s-triglycerides −0.39 0.028 (0.14) −0.39 0.26 (1) −0.36 0.10 (0.50) 0.51 0.003 (0.027) 0.73 0.018 (0.22) 0.41 0.061 (0.30)
s-HDL 0.43 0.019 (0.13) −0.04 0.92 (1) 0.57 0.009 (0.11) −0.31 0.10 (0.28) 0.14 0.71 (0.84) −0.59 0.006 (0.072)
s-Adiponectin 0.46 0.009 (0.081) 0.37 0.29 (1) 0.42 0.05 (0.31) −0.54 0.001 (0.012) −0.71 0.022 (0.24) −0.55 0.008 (0.088)
s-RBP4 −0.61 0.003 (0.036) −0.43 0.26 (1) −0.59 0.034 (0.31) 0.41 0.059 (0.26) 0.53 0.14 (0.84) 0.40 0.18 (0.72)
GLUT4 mRNA 0.49 0.011 (0.088) 0.18 0.62 (1) 0.49 0.02 (0.22) −0.40 0.023 (0.18) −0.44 0.21 (0.84) −0.45 0.034 (0.27)
GLUT4
protein
0.51 0.004 (0.044) 0.57 0.11 (1) 0.45 0.034 (0.31) −0.35 0.051 (0.26 −0.59 0.095 (0.76) −0.27 0.23 (0.72)
Adipose cell
size
−0.40 0.022 (0.13) −0.40 0.26 (1) −0.44 0.043 (0.31) ––––––
GIR Glucose infusion rate during the euglycemic clamp.
WHR waist/hip ratio.
Pcorr: P-value Bonferroni-Holm corrected.
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A number of studies have established that adipose tissue
dysfunction contributes to metabolic dysfunction and
type 2 diabetes. Enlargement of adipocyte cell size has
been shown to be associated with adipose tissue dys-
function and, in addition, to predict later development
of type 2 diabetes in Pima Indians, a population with
high propensity for obesity and type 2 diabetes [20], as
well as in a Swedish cohort of middle-aged women [21].
Although obesity is a major risk factor for the develop-
ment of type 2 diabetes, not all obese individuals be-
come insulin resistant or develop type 2 diabetes.
Recently, it was shown by Klöting et al. [22] that insulin-
sensitive, severely obese individuals have smaller adipo-
cyte size compared to an equally obese group matched
for age, sex and body fat. This finding was also asso-
ciated with reduced tissue inflammation and higher
insulin-stimulated glucose uptake at least in omental
Figure 1 Adipocyte cell size correlations. (A) Adipocyte cell size is positively correlated to circulating triglycerides (R=0.51, p=0.003) and
circulating insulin levels (R=0.52, p=0.002). (B) Adipose cell size (R=−0.54, p=0.001), WHR (R=−0.63, p<0.001) and BMI (R=−0.35, p=0.05)
are all significantly and inversely associated with circulating adiponectin levels. (C) Adipose cell size tends to be negatively associated with the
expression the glucose transporter GLUT4 protein (R=−0.35, p=0.051) and is negatively associated with mRNA (R=−0.40, p=0.023) in the
adipose tissue in non-obese subjects.
Figure 2 Circulating factors. (A) Circulating total adiponectin level tends to correlate with GLUT4 mRNA (R=0.34, p=0.059) and protein
(R=0.32, p=0.08) expression in the adipose tissue and is negatively correlated with circulating serum RBP4 levels (R=−0.54, p=0.009).
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subjects with a known genetic predisposition for either
type 2 diabetes or obesity, we have recently shown that
for a given amount of body fat individuals with a genetic
predisposition for type 2 diabetes had an inappropriate
enlargement of their abdominal adipocyte cell size. This
difference was evident when they were compared to sub-
jects with a genetic predisposition for obesity or to con-
trol subjects lacking a known genetic predisposition
[23]. These findings indicate that adipocyte hypertrophy
combined with an “obese phenotype” is present in the
abdominal adipose tissue long before type 2 diabetes
develops and that this is related to insulin resistance
rather than obesity per se. Clearly, adipocyte cell size
and function are related to whole body insulin
sensitivity.
The cohort studied in this report was part of the inter-
European EUGENE 2 program (www.eugene2.com) [14].
This program focused on carefully phenotyping indivi-
duals at risk for type 2 diabetes by virtue of having at
least one first degree relative with this condition. This
cohort has undergone several genotyping studies and is
followed prospectively in order to identify future dia-
betes development. The individuals included in this
study were healthy and non-obese, but they are a high-
risk group even though current obesity was not part of
the risk profile. Furthermore, they are more insulin-
resistant, as a group, than matched control subjects with-
out a family history of type 2 diabetes [5].
The results from the present study show that markers
of adipose tissue dysregulation are present already in
these otherwise healthy individuals. Adipose cell size,
GLUT 4 protein and mRNA expression as well as circu-
lating levels of adiponectin and RBP4 were all markers
for degree of insulin sensitivity. Interestingly, adipose
cell size was positively correlated with serum RBP4,
which is consistent with previous findings [24], and in-
versely with adiponectin levels as well as with GLUT 4
expression. These findings are consistent with the con-
cept that adipose cell expansion, even over the limited
range of BMI in this cohort, is associated with insulin
resistance as well as markers of a dysregulated adipose
tissue measured as low GLUT4 expression and circulat-
ing levels of adiponectin and high serum RBP4 levels.
The associations also suggest that these molecules may
have common gene regulatory sites such as C/EBPalpha
although no correlation was found between mRNA
levels for this transcription factor and adiponectin or
Table 3 Correlation between phenotype and circulating adiponectin levels
Adiponectin
All Men Women
R-value P-value (Pcorr) R-value P-value (Pcorr) R-value P-value (Pcorr)
BMI −0.35 0.05 (0.20) −0.69 0.028 (0.25) −0.18 0.42 (1)
WHR −0.63 <0.001 (0.01) −0.67 0.034 (0.27) −0.52 0.014 (0.14)
Glucose −0.35 0.052 (0.20) −0.49 0.15 (0.60) 0.05 0.84 (1)
Insulin −0.43 0.013 (0.091) −0.64 0.047 (0.31) −0.34 0.12 (0.96)
HbA1c −0.39 0.03 (0.18) −0.35 0.32 (0.96) −0.27 0.22 (1)
s-triglycerides −0.38 0.032 (0.18) −0.64 0.044 (0.31) −0.15 0.49 (1)
s-HDL 0.50 0.005 (0.045) 0.27 0.45 (0.96) 0.52 0.019 (0.17)
s-RBP4 −0.54 0.009 (0.072) 0.62 0.08 (0.40) 0.43 0.14 (0.98)
GLUT4 mRNA 0.34 0.059 (0.20) 0.79 0.006 (0.06) 0.18 0.43 (1)
GLUT4 protein 0.32 0.083 (0.20) 0.34 0.37 (0.96) 0.16 0.49 (1)
WHR waist/hip ratio.
Pcorr P-value Bonferroni-Holm corrected.
Table 4 Correlation between phenotype and HIF-1alpha
and VEGF expression
HIF-1alpha VEGF
R-value P-value (Pcorr) R-value P-value (Pcorr)
BMI −0.15 0.54 (1) −0.14 0.62 (1)
WHR 0.03 0.89 (1) −0.56 0.032 (0.42)
Glucose 0.13 0.61 (1) −0.24 0.39 (1)
Insulin 0.07 0.76 (1) −0.16 0.57 (1)
HbA1c 0.15 0.55 (1) −0.10 0.73 (1)
GIR −0.17 0.48 (1) 0.23 0.42 (1)
s-triglycerides −0.06 0.80 (1) −0.44 0.10 (1)
s-HDL −0.06 0.82 (1) 0.22 0.46 (1)
s-Adiponectin −0.08 0.76 (1) 0.43 0.11 (1)
s-RBP4 0.28 0.26 (1) −0.07 0.81 (1)
GLUT4 mRNA 0.08 0.74 (1) 0.54 0.039 (0.47)
GLUT4 protein −0.23 0.36 (1) 0.43 0.12 (1)
Adipose cell size 0.06 0.80 (1) −0.04 0.89 (1)
GIR Glucose infusion rate during the euglycemic clamp.
WHR waist/hip ratio.
Pcorr: P-value Bonferroni-Holm corrected.
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not measure APM1 mRNA levels since this molecule is
subject to important post-transcriptional modifications
as well as a regulated secretion pathway [25], thus mak-
ing mRNA levels less dependent than total protein
secreted and present in the blood. Virtually all clinical
studies on the role of adiponectin have also focused on
the circulating levels of this protein. It is also noteworthy
that while circulating adiponectin levels were only
border-line correlated to BMI and serum RBP4 levels
not at all, the association with adipose cell size was
highly significant. These findings are in line with the
results presented by Klöting et al. where circulating adi-
ponectin is decreased and RBP4 increased in equally
obese individuals with enlarged adipocytes and reduced
insulin sensitivity [26].
Interestingly, insulin sensitivity was most closely related
to waist/hip ratio and adipose cell size while BMI was a
poor marker. The lack of correlation with BMI is probably
due to the relatively limited range of BMI in this cohort
since BMI is well known to be associated with insulin sensi-
tivity in large population samples with different degree of
obesity. Thus, this study shows that adipose cell size and
adipose tissue distribution are more sensitive parameters
over a relatively limited range of BMI in a cohort of non-
obese subjects. In addition, these results show that adipose
tissue dysregulation does not require obesity per se but ra-
ther hypertrophic adipose cells. The hypertrophic charac-
teristics of the adipose tissue is probably due to inability to
recruit and/or differentiate preadipocytes which results in
excessive lipid deposition in, and enlargement of, pre-
existing adipocytes. We recently found that even though
precursor cells are available in adipose tissue there seems to
be a blockage of the commitment and/or initiation of adi-
pocyte differentiation leading to impaired preadipocyte re-
cruitment in individuals with enlarged fat cells [7]. This is
in line with recent findings showing that the number of
new adipocytes generated each year is reduced in subjects
with adipocyte hypertrophy while the relative death rate is
unchanged [27]. What constitutes the blockage is still un-
known, but clearly the resulting adipocyte hypertrophy is
associated with adipose tissue dysfunction. We here show
that this is also related to reduced insulin sensitivity com-
bined with a metabolic risk profile and markers of adipose
tissue dysregulation. It is well known that adipose tissue
distribution differs between men and women but, inter-
estingly, it has also been shown that the proportion of
early-differentiated adipocytes, measured as percentage of
PPARgamma expressing cells in the subcutaneous adipose
tissue is increased in women when compared to men in-
dicating that there may be important gender-related dif-
ferences in pre-adipocyte recruitment, proliferation and
differentiation potential [28]. Our results show that the
correlation between adipocyte cell size and GLUT4 as well
as the insulin resistance marker RBP4 are affected by gen-
der. This is also true for the association between adipo-
nectin and GLUT4, both markers of late adipocyte
differentiation and function. These findings add further
strength to the concept of gender differences in adipocyte
differentiation and function. Tchoukalova et al. speculate
that a possible mechanism could include gender-specific
differences in the micro-environment and/or effects of sex-
steroid hormones. Sex steroid-hormones have been shown
to influence fat distribution [29] as well as adipocyte differ-
entiation [30] and could well be responsible for the gender
differences observed. Unfortunately, we did not measure
sex-steroids in the present study. However, a recent paper
investigating clinical characteristics associated with insulin
sensitivity in women with polycystic ovary syndrome
(PCOS) showed that the strongest predictors of insulin
sensitivity in this group were adipocyte cell size, adipo-
nectin and WHR, while sex steroid-hormones were
excluded from the regression model [31]. Further studies
are required to elucidate the importance of, and mechan-
isms behind, these gender-associated differences.
It is well established that enlarged adipose cells leads
to infiltration of macrophages and other inflammatory
cells, including mast cells [32-34]. The presence of in-
flammatory cells in the adipose tissue affects the micro-
environment and can impair adipocyte differentiation
[7,17]. Indeed, macrophage infiltration in the omental
adipose tissue depot, together with circulating adiponec-
tin was found to almost completely explain the degree of
insulin sensitivity in severely obese individuals [26]. We
previously measured the inflammatory cytokine IL6 in
adipose tissue and showed that expression, secretion
and, as a consequence, also interstitial levels of this cyto-
kine were increased in the adipose tissue characterized
by enlarged fat cells [18]. Thus, inflammation seems to
follow adipose cell size enlargement and this is also
associated with impaired adipocyte differentiation [35].
Cellular hypoxia has also been implicated in adipose tis-
sue dysregulation in obesity [19]. However, we found no
relationship between HIF-1alpha mRNA levels, or
VEGF, which is an HIF-1alpha-regulated gene [36], and
adipose cell size or any marker of insulin resistance. This
is in agreement with previously reports in obese indivi-
duals where the expression in subcutaneous adipose tis-
sue was unrelated to the degree of insulin sensitivity or
cell size. In contrast, the expression of HIF-1alpha has
been shown to be up-regulated in insulin resistant
omental adipose tissue in severe obese individuals [26].
Thus, although HIF-1alpha may play a role in severe
obesity, we did not find any association between insulin
sensitivity and HIF-1alpha in this small group of indivi-
duals with hypertrophic adipocytes.
The results of the present study clearly show that
enlarged abdominal adipose cells are associated with
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whether obesity is present or not.
A likely reason for the insulin resistance is altered
RBP4 and adiponectin levels as well as an inability to
store additional lipids in the subcutaneous depot during
weight gain. This leads to storage in ectopic sites includ-
ing visceral depots, liver and muscle which, in turn, fur-
ther promotes insulin resistance (Reviewed in [15,37]).
Elegant experiments in mouse models have indeed
shown that mice overexpressing adiponectin in the sub-
cutaneous adipose tissue become grossly obese with
hypercellular adiposity as a consequence of new preadi-
pocyte recruitment and differentiation. The changes
associated with this transgene did not impair insulin
sensitivity at all [8]. The present results further support
the concept that pre-adipocyte recruitment and hyper-
cellular obesity can prevent the development of insulin
resistance.
The present study is limited by its small number of
subjects and using the quite conservative methods avail-
able to correct for multiple testing leaves few significant
correlations. However, regardless of these limitations,
the results provide important information in a high-risk
cohort of first-degree relatives to type 2 diabetic patients
showing that a dysregulated adipose tissue occurs early
and is associated with insulin resistance. Future studies,
such as long-term follow-up studies of the EUGENE 2
cohorts may provide further evidence for this concept as
a risk to develop type 2 diabetes as well.
Conclusion
The findings in the present paper support the concept
that it is not obesity per se, but rather metabolic dys-
function in the adipose tissue that is associated with sys-
temic insulin resistance and the metabolic syndrome.
Future prospective studies may provide final evidence of
this concept and the relative importance of its different
components.
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